Novel sulphur containing lipids for use as food supplement or as medicament

A method for the treatment of a disease or condition chosen from a dyslipidemic condition;

• elevated triglyceride levels, LDL cholesterol levels, and/or VLDL cholesterol levels;
• peripheral insulin resistance;
• and/or a diabetic condition in a subject in need thereof, comprising administering to the subject a pharmaceutically active amount of
• 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenylthio)butanoic acid.

A method for the treatment of atherosclerosis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of formula (I):

• wherein
• R1 is chosen from a C10-C22 alkenyl group having 3-6 methylene interrupted double bonds in Z configuration and a C10-C22 alkynyl group having 1-6 triple bonds;
• R2 and R3 are the same or different and each are independently chosen from a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, a carboxy group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, or an alkylamino group, provided that R2 and R3 are not both a hydrogen atom;
• or
• R2 and R3 are connected in order to form a cycloalkane;
• Y is chosen from sulphur, sulfoxide, and sulfone;
• and
• X is a carboxylic acid or a derivative thereof, wherein the derivative is a carboxylic ester, a carboxamide, a monoglyceride, a diglyceride, a triglyceride, or a phospholipid;
• or a pharmaceutically acceptable salt thereof.

A method for the treatment myocardial infarction and/or an inflammatory disease or condition in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of formula (I):

• wherein
• R1 is chosen from a C10-C22 alkenyl group having 3-6 methylene interrupted double bonds in Z configuration and a C10-C22 alkynyl group having 1-6 triple bonds;
• R2 and R3 are the same or different and each are independently chosen from a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, a carboxy group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, or an alkylamino group, provided that R2 and R3 are not both a hydrogen atom;
• or
• R2 and R3 are connected in order to form a cycloalkane;
• Y is chosen from sulphur, sulfoxide, and sulfone;
• and
• X is a carboxylic acid or a derivative thereof, wherein the derivative is a carboxylic ester, a carboxamide, a monoglyceride, a diglyceride, a triglyceride, or a phospholipid;
• or a pharmaceutically acceptable salt thereof.